aidsВИЧ-инфекция и иммуносупрессииHIV Infection and Immunosuppressive Disorders2077-9828Baltic Medical Education Center10.22328/2077-9828-2017-9-2-16-26aids-255Research ArticleАНАЛИТИЧЕСКИЙ ОБЗОРANALYTICAL REVIEWЗЛОКАЧЕСТВЕННЫЕ ОПУХОЛИ ПРИ ВИЧ-ИНФЕКЦИИ. ЛОКАЛИЗАЦИЯ, ПРОФИЛАКТИКА, ЛЕЧЕНИЕ. ЧАСТЬ 2MALIGNANT TUMORS IN HIV PATIENTS. LOCALIZATION, PREVENTION, AND TREATMENT. PART 2РассохинВ. В.RassokhinV. V.

Рассохин Вадим Владимирович — доктор медицинских наук, профессор кафедры социально-значимых инфекций ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П.Павлова» МЗ РФ; ведущий научный сотрудник ФБУН «Санкт-Петербургский НИИ эпидемиологии и микро- биологии имени Пастера» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека; зав. лаборатории хронических вирусных инфекций ФГБНУ «Институт экспериментальной медицины».

197376, Санкт-Петербург, ул. Академика Павлова, 12.

ras-doc@mail.ruНекрасоваА. В.NekrasovaA. V.

Некрасова Анастасия Викторовна — врач-онколог отделения онкологии № 2 (ХТ и ТКМ) НИИ детской онкологии, гематологии и трансплантологии им. Р.М. Горбачевой ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика   И.П. Павлова» МЗ РФ; научный сотрудник ФГБНУ «Институт экспериментальной медицины».

197376, Санкт-Петербург, ул. Академика Павлова, 12. 

9095842005onco@mail.ruБеляковН. А.BelyakovN. A.

Беляков Николай Алексеевич — академик РАН, зав. кафедрой социально-значимых инфекций ФГБОУ ВО «Первый Санкт-Петербургский госу- дарственный медицинский университет имени академика И.П. Павлова» МЗ РФ; главный научный сотрудник ФГБНУ «Институт экспериментальной медицины»; руководитель Северо-Западного окружного центра по профилактике и борьбе со СПИДом ФБУН «Санкт-Петербургский НИИ эпидемиологии и микробиологии имени Пастера» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека.

197101, Санкт-Петербург, ул. Мира, 14.

beliakov.akad.spb@yandex.ruФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» МЗ РФ; ФБУН «Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии имени Пастера» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека; ФГБНУ «Институт экспериментальной медицины».РоссияFSBEI HE I.P. Pavlov SPbMU MON; Saint-Petersburg Paster Institute; FSBSI «IEM».Russian FederationФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» МЗ РФ; ФГБНУ «Институт экспериментальной медицины».РоссияFSBEI HE I.P. Pavlov SPbMU MON; FSBSI «IEM».Russian Federation201707072017921626Copyright © Рассохин В.В., Некрасова А.В., Беляков Н.А., 20172017Рассохин В.В., Некрасова А.В., Беляков Н.А.Rassokhin V.V., Nekrasova A.V., Belyakov N.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://hiv.bmoc-spb.ru/jour/article/view/255

Первая часть обзора с освещением эпидемиологии, патогенеза и видов опухолей опубликована в нашем журнале (2017. Т. 9, № 1). Во второй части рассмотрены локализации опухолей, вопросы профилактики и лечения. Отмечается, что по мере развития эпидемии будет увеличиваться число опухолей, требуется продолжать междисциплинарные исследования по всем направлениям, что дает перспективы в более успешной борьбе со злокачественными новообразованиями при инфекции вирусом иммунодефицита человека.

The first part of this review has been published in the previous issue of this journal. The second part addresses tumor location, prevention, and treatment. Any further development of HIV epidemic will be associated with that tumor prevalence will increase. Further interdisciplinary research aimed at improving the control of malignancies in HIV patients is thus warranted.

ВИЧ-инфекцияСПИДзлокачественные новообразованияиммуносупрессияскринингантиретро- вирусная терапияпрофилактикаHIV infectionAIDSmalignant neoplasmsimmunosuppressionscreeningantiretroviral therapyprevention.ReferencesHo-Yen C., Chang F., VanDer Walt J., Lucas S. Gastrointestinal malignancies in HIV-infected or immunosuppressed patients: pathologic featu- res and review of the literature. Adv. Anat. Pathol., 2007, Vol. 14, No. 6, рр. 431–443.Ho-Yen C., Chang F., VanDer Walt J., Lucas S. Gastrointestinal malignancies in HIV-infected or immunosuppressed patients: pathologic featu- res and review of the literature. Adv. Anat. Pathol., 2007, Vol. 14, No. 6, рр. 431–443.Renwick N., Halaby T., Weverling G.J., Dukers N.H.T.M., Simpson G.R., Coutinho R.A., Lange J.M.A., Schulz T.F., Goudsmit J. Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi’s sarcoma. AIDS, 1998, Vol. 12, No. 18, рр. 2481–2488.Renwick N., Halaby T., Weverling G.J., Dukers N.H.T.M., Simpson G.R., Coutinho R.A., Lange J.M.A., Schulz T.F., Goudsmit J. Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi’s sarcoma. AIDS, 1998, Vol. 12, No. 18, рр. 2481–2488.Krown S.E., Metroka C., Wernz J.C. Kaposi’s sarcoma in the acquired immune deficiency syndrome: A proposal for uniform evaluation, response, and staging criteria. J. Clin. Oncol., 1989, Vol. 7, No. 9, рр. 1201–1207.Krown S.E., Metroka C., Wernz J.C. Kaposi’s sarcoma in the acquired immune deficiency syndrome: A proposal for uniform evaluation, response, and staging criteria. J. Clin. Oncol., 1989, Vol. 7, No. 9, рр. 1201–1207.Nawar E., Mbulaiteye S., Gallant J.E., Wohl D.A., Ardini M., Hendershot T. et al. Risk factors for Kaposi’s sarcoma among HHV-8 seropositive homosexual men with AIDS. Int. J. Cancer., 2005, Vol. 115, No. 2, рр. 296–300.Nawar E., Mbulaiteye S., Gallant J.E., Wohl D.A., Ardini M., Hendershot T. et al. Risk factors for Kaposi’s sarcoma among HHV-8 seropositive homosexual men with AIDS. Int. J. Cancer., 2005, Vol. 115, No. 2, рр. 296–300.Barrison I.G., Foster S., Harris J.W., Pinching A.J., Walker J.G. Upper gastrointestinal Kaposi’s sarcoma in patients positive for HIV antibody without cutaneous disease. Br. Med. J. (Clin. Res. Ed.), 1988, Vol. 296, No. 6615, рр. 92–93.Barrison I.G., Foster S., Harris J.W., Pinching A.J., Walker J.G. Upper gastrointestinal Kaposi’s sarcoma in patients positive for HIV antibody without cutaneous disease. Br. Med. J. (Clin. Res. Ed.), 1988, Vol. 296, No. 6615, рр. 92–93.Wang N.C., Chang F.Y., Chou Y.Y., Chiu C.L., Lin C.K., Ni Y.H., Liu Y.C. Intussusception as the initial manifestation of AIDS associated with primary Kaposi’s sarcoma: a case report. J. Formos Med. Assoc., 2002, Vol. 101, No. 8, рр. 585–587.Wang N.C., Chang F.Y., Chou Y.Y., Chiu C.L., Lin C.K., Ni Y.H., Liu Y.C. Intussusception as the initial manifestation of AIDS associated with primary Kaposi’s sarcoma: a case report. J. Formos Med. Assoc., 2002, Vol. 101, No. 8, рр. 585–587.Neville C.R., Peddada A.V., Smith D., Kagan A.R., Frost D.B., Sadoff L. Massive gastrointestinal hemorrhage from AIDS-related Kaposi’s sar- coma confined to the small bowel managed with radiation. Medical and Pediatric Oncology, 1996, Vol. 26, No. 2, рр. 135–138.Neville C.R., Peddada A.V., Smith D., Kagan A.R., Frost D.B., Sadoff L. Massive gastrointestinal hemorrhage from AIDS-related Kaposi’s sar- coma confined to the small bowel managed with radiation. Medical and Pediatric Oncology, 1996, Vol. 26, No. 2, рр. 135–138.Krause J. AIDS-related non-Hodgkin’s lymphomas. Microscopy Research and Technique, 2005, Vol. 68, No. 3–4, рр. 168–175.Krause J. AIDS-related non-Hodgkin’s lymphomas. Microscopy Research and Technique, 2005, Vol. 68, No. 3–4, рр. 168–175.Carbone A. AIDS-related non-Hodgkin’s lymphomas: From pathology and molecular pathogenesis to treatment Hum. Pathol., 2002, Vol. 33, No. 4, рр. 392–404.Carbone A. AIDS-related non-Hodgkin’s lymphomas: From pathology and molecular pathogenesis to treatment Hum. Pathol., 2002, Vol. 33, No. 4, рр. 392–404.Clark M.A., Hartley A., Geh J.I. Cancer of the anal canal. Lancet Oncology, 2004, Vol. 5, No. 3, рр. 149–157.Clark M.A., Hartley A., Geh J.I. Cancer of the anal canal. Lancet Oncology, 2004, Vol. 5, No. 3, рр. 149–157.Ryan D.P., Mayer R.J. Anal carcinoma: histology, staging, epidemiology, treatment. Curr. Opin. Oncol., 2000, Vol. 12, No. 4, рр. 345–352.Ryan D.P., Mayer R.J. Anal carcinoma: histology, staging, epidemiology, treatment. Curr. Opin. Oncol., 2000, Vol. 12, No. 4, рр. 345–352.Williams G.R., Talbot I.C. Anal carcinoma: a histological review. Histopathology, 1994, Vol. 25, No. 0309–0167 (Print), рр. 507–516.Williams G.R., Talbot I.C. Anal carcinoma: a histological review. Histopathology, 1994, Vol. 25, No. 0309–0167 (Print), рр. 507–516.Zbar A.P., Fenger C., Efron J., Beer-Gabel M., Wexner S.D. The pathology and molecular biology of anal intraepithelial neoplasia: Comparisons with cervical and vulvar intraepithelial carcinoma. Int. J. Colorectal Dis., 2002, Vol. 17, No. 4, рр. 203–215.Zbar A.P., Fenger C., Efron J., Beer-Gabel M., Wexner S.D. The pathology and molecular biology of anal intraepithelial neoplasia: Comparisons with cervical and vulvar intraepithelial carcinoma. Int. J. Colorectal Dis., 2002, Vol. 17, No. 4, рр. 203–215.Palefsky J.M., Holly E.A., Hogeboom C.J., Ralston M.L., DaCosta M.M., Botts R., Berry J.M., Jay N., Darragh T.M. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. International Retrovirology Association, 1998, Vol. 17, No. 4, рр. 314–319.Palefsky J.M., Holly E.A., Hogeboom C.J., Ralston M.L., DaCosta M.M., Botts R., Berry J.M., Jay N., Darragh T.M. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. International Retrovirology Association, 1998, Vol. 17, No. 4, рр. 314–319.Martin F., Bower M. Anal intraepithelial neoplasia in HIV positive people. Sex. Transm. Infect., 2001, Vol. 77, No. 5, рр. 327–331.Martin F., Bower M. Anal intraepithelial neoplasia in HIV positive people. Sex. Transm. Infect., 2001, Vol. 77, No. 5, рр. 327–331.Bräu N., Fox R.K., Xiao P., Marks K., Naqvi Z., Taylor L.E., Trikha A., Sherman M., Sulkowski M.S., Dieterich D.T., Rigsby M.O., Wright T.L., Hernandez M.D., Jain M.K., Khatri G.K., Sterling R.K., Bonacini M., Martyn C.A., Aytaman A., Llovet J.M., Brown S.T., Bini E.J. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.-Canadian multicenter study. J. Hepatol., 2007, Vol. 47, No. 4, рр. 527–537.Bräu N., Fox R.K., Xiao P., Marks K., Naqvi Z., Taylor L.E., Trikha A., Sherman M., Sulkowski M.S., Dieterich D.T., Rigsby M.O., Wright T.L., Hernandez M.D., Jain M.K., Khatri G.K., Sterling R.K., Bonacini M., Martyn C.A., Aytaman A., Llovet J.M., Brown S.T., Bini E.J. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.-Canadian multicenter study. J. Hepatol., 2007, Vol. 47, No. 4, рр. 527–537.Berretta M., Di Benedetto F., Dal Maso L., Cacopardo B., Nasti G., Facchini G. et al. Hepatocellular carcinoma in HIV-infected patients: check early, treat hard. Oncologist, 2011, Vol. 16, No. 9, рр. 1258–1269.Berretta M., Di Benedetto F., Dal Maso L., Cacopardo B., Nasti G., Facchini G. et al. Hepatocellular carcinoma in HIV-infected patients: check early, treat hard. Oncologist, 2011, Vol. 16, No. 9, рр. 1258–1269.Yopp A.C., Subramanian M., Jain M.K., Mansour J.C., Schwarz R.E., Balch G.C., Singal A.G. Presentation, treatment, and clinical outco.mes of patients with hepatocellular carcinoma, with and without human immunodeficiency virus infection. Clin. Gastroenterol. Hepatol., 2012, Vol. 10, No. 11, рр. 1284–1290.Yopp A.C., Subramanian M., Jain M.K., Mansour J.C., Schwarz R.E., Balch G.C., Singal A.G. Presentation, treatment, and clinical outco.mes of patients with hepatocellular carcinoma, with and without human immunodeficiency virus infection. Clin. Gastroenterol. Hepatol., 2012, Vol. 10, No. 11, рр. 1284–1290.Shiels M.S., Cole S.R., Mehta S.H., Kirk G.D. Lung cancer incidence and mortality among HIV-infected and HIV-uninfected injection drug users. J. Acquir. Immune Defic. Syndr., 2010, Vol. 55, No. 4, рр. 510–515.Shiels M.S., Cole S.R., Mehta S.H., Kirk G.D. Lung cancer incidence and mortality among HIV-infected and HIV-uninfected injection drug users. J. Acquir. Immune Defic. Syndr., 2010, Vol. 55, No. 4, рр. 510–515.Sigel K., Wisnivesky J., Gordon K., Dubrow R., Justice A., Brown S.T., Goulet J., Butt A.A., Crystal S., Rimland D., Rodriguez-Barradas M., Gibert C., Park L.S., Crothers K. HIV as an independent risk factor for incident lung cancer. AIDS, 2012, Vol. 26, No. 8, рр. 1017–1025.Sigel K., Wisnivesky J., Gordon K., Dubrow R., Justice A., Brown S.T., Goulet J., Butt A.A., Crystal S., Rimland D., Rodriguez-Barradas M., Gibert C., Park L.S., Crothers K. HIV as an independent risk factor for incident lung cancer. AIDS, 2012, Vol. 26, No. 8, рр. 1017–1025.Sigel K., Pitts R., Crothers K. Lung Malignancies in HIV Infection Semin. Respir. Crit. Care Med., 2016, Vol. 37, No. 2, рр. 267–276.Sigel K., Pitts R., Crothers K. Lung Malignancies in HIV Infection Semin. Respir. Crit. Care Med., 2016, Vol. 37, No. 2, рр. 267–276.Mani D., Haigentz M.J., Aboulafia D.M. Lung cancer in HIV Infection. Clin. Lung Cancer, 2012, Vol. 13, No. 1, рр. 6–13.Mani D., Haigentz M.J., Aboulafia D.M. Lung cancer in HIV Infection. Clin. Lung Cancer, 2012, Vol. 13, No. 1, рр. 6–13.Bazot M., Cadranel J., Khalil A., Benayoun S., Milleron B., Bigot J.M., Carette M.F. Computed tomographic diagnosis of bronchogenic carcino- ma in HIV-infected patients. Lung Cancer, 2000, Vol. 28, No. 3, рр. 203–209.Bazot M., Cadranel J., Khalil A., Benayoun S., Milleron B., Bigot J.M., Carette M.F. Computed tomographic diagnosis of bronchogenic carcino- ma in HIV-infected patients. Lung Cancer, 2000, Vol. 28, No. 3, рр. 203–209.Karp J., Profeta G., Marantz P.R., Karpel J.P. Lung cancer in patients with immunodeficiency syndrome. Chest, 1993, Vol. 103, No. 2, рр. 410–413.Karp J., Profeta G., Marantz P.R., Karpel J.P. Lung cancer in patients with immunodeficiency syndrome. Chest, 1993, Vol. 103, No. 2, рр. 410–413.Brock M.V., Hooker C.M., Engels E.A., Moore R.D., Gillison M.L., Alberg A.J., Keruly J.C., Yang S.C., Heitmiller R.F., Baylin S.B., Herman J.G., Brahmer J.R. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J. Acquir. Immune Defic. Syndr., 2006, Vol. 43, No. 1, рр. 47–55.Brock M.V., Hooker C.M., Engels E.A., Moore R.D., Gillison M.L., Alberg A.J., Keruly J.C., Yang S.C., Heitmiller R.F., Baylin S.B., Herman J.G., Brahmer J.R. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J. Acquir. Immune Defic. Syndr., 2006, Vol. 43, No. 1, рр. 47–55.Bhargava P., Parker J.A., Dezube B.J. Pitfalls of diagnosis based on abnormal flow cytometry and [(18)F]fluorodeoxyglucose positron emission tomography. Clin. Lymphoma Myeloma. Elsevier Inc., 2008, Vol. 8, No. 2, рр. 117–120.Bhargava P., Parker J.A., Dezube B.J. Pitfalls of diagnosis based on abnormal flow cytometry and [(18)F]fluorodeoxyglucose positron emission tomography. Clin. Lymphoma Myeloma. Elsevier Inc., 2008, Vol. 8, No. 2, рр. 117–120.Cadranel J., Garfield D., Lavole A., Wislez M., Milleron B., Mayaud C. Lung cancer in HIV infected patients: facts, questions and challenges. Thorax, 2006, Vol. 61, No. 11, рр. 1000–1008.Cadranel J., Garfield D., Lavole A., Wislez M., Milleron B., Mayaud C. Lung cancer in HIV infected patients: facts, questions and challenges. Thorax, 2006, Vol. 61, No. 11, рр. 1000–1008.Sorensen P. Manifestations of HIV in the head and neck. Curr. Infect. Dis. Rep., 2011, Vol. 13, No. 2, рр. 115–122.Sorensen P. Manifestations of HIV in the head and neck. Curr. Infect. Dis. Rep., 2011, Vol. 13, No. 2, рр. 115–122.Singh B. Head and neck manifestations of non-Hodgkin’s lymphoma in human immunodeficiency virus-infected patients. Am. J. Otolaryngol., 2000, Vol. 21, No. 1, рр. 10–13.Singh B. Head and neck manifestations of non-Hodgkin’s lymphoma in human immunodeficiency virus-infected patients. Am. J. Otolaryngol., 2000, Vol. 21, No. 1, рр. 10–13.Purgina B., Pantanowitz L., Seethala R.R. A Review of Carcinomas Arising in the Head and Neck Region in HIV-Positive Patients. Patholog. Res. Int., 2011, Vol. 2011, рр. 469–150.Purgina B., Pantanowitz L., Seethala R.R. A Review of Carcinomas Arising in the Head and Neck Region in HIV-Positive Patients. Patholog. Res. Int., 2011, Vol. 2011, рр. 469–150.Sarhan M., DePaz H.A., Oluwole S.F.D. Breast cancer in women with human immunodeficiency virus infection: pathological, clinical, and pro- gnostic implications. J. Womens Health (Larchmt), 2010, Vol. 19, No. 12, рр. 2261–2266.Sarhan M., DePaz H.A., Oluwole S.F.D. Breast cancer in women with human immunodeficiency virus infection: pathological, clinical, and pro- gnostic implications. J. Womens Health (Larchmt), 2010, Vol. 19, No. 12, рр. 2261–2266.Oluwole S.F., Ali A.O., Shafaee Z., DePaz H.A. Breast cancer in women with HIV/AIDS: Report of five cases with a review of the literature. J. Surg. Oncol., 2005, Vol. 89, No. 1, рр. 23–27.Oluwole S.F., Ali A.O., Shafaee Z., DePaz H.A. Breast cancer in women with HIV/AIDS: Report of five cases with a review of the literature. J. Surg. Oncol., 2005, Vol. 89, No. 1, рр. 23–27.Chawki S., Ploussard G., Montlahuc C., Verine J., Mongiat-Artus P., Desgrandchamps F., Molina J.M. Bladder cancer in HIV-infected adults: an emerging concern? J. Int. AIDS Soc., 2014, Vol. 17, No. 4, Suppl. 3, рр. 19–647.Chawki S., Ploussard G., Montlahuc C., Verine J., Mongiat-Artus P., Desgrandchamps F., Molina J.M. Bladder cancer in HIV-infected adults: an emerging concern? J. Int. AIDS Soc., 2014, Vol. 17, No. 4, Suppl. 3, рр. 19–647.Pantanowitz L., Bohac G., Cooley T.P., Aboulafia D., Dezube B.J. Human immunodeficiency virus-associated prostate cancer: Clinicopathological findings and outcome in a multi-institutional study. BJU Int., 2008, Vol. 101, No. 12, рр. 1519–1523.Pantanowitz L., Bohac G., Cooley T.P., Aboulafia D., Dezube B.J. Human immunodeficiency virus-associated prostate cancer: Clinicopathological findings and outcome in a multi-institutional study. BJU Int., 2008, Vol. 101, No. 12, рр. 1519–1523.Rubinstein P.G., Aboulafia D.M., Zloza A. Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges. AIDS, 2014, Vol. 28, No. 4, рр. 453–465.Rubinstein P.G., Aboulafia D.M., Zloza A. Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges. AIDS, 2014, Vol. 28, No. 4, рр. 453–465.Hentrich M., Berger M., Wyen C., Siehl J., Rockstroh J.K., Müller M., Fätkenheuer G., Seidel E., Nickelsen M., Wolf T., Rieke A., Schürmann D. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J. Clin. Oncol., 2012, Vol. 30, No. 33, рр. 4117–4123.Hentrich M., Berger M., Wyen C., Siehl J., Rockstroh J.K., Müller M., Fätkenheuer G., Seidel E., Nickelsen M., Wolf T., Rieke A., Schürmann D. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J. Clin. Oncol., 2012, Vol. 30, No. 33, рр. 4117–4123.Sparano J.A., Lee J.Y., Kaplan L.D., Levine A.M., Ramos J.C., Ambinder R.F., Wachsman W., Aboulafia D., Noy A., Henry D.H., Von Roenn J., Dezube B.J., Remick S.C., Shah M.H., Leichman L., Ratner L., Cesarman E., Chadburn A., Mitsuyasu R. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood, 2010, Vol. 115, No. 15, рр. 3008–3016.Sparano J.A., Lee J.Y., Kaplan L.D., Levine A.M., Ramos J.C., Ambinder R.F., Wachsman W., Aboulafia D., Noy A., Henry D.H., Von Roenn J., Dezube B.J., Remick S.C., Shah M.H., Leichman L., Ratner L., Cesarman E., Chadburn A., Mitsuyasu R. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood, 2010, Vol. 115, No. 15, рр. 3008–3016.Oehler-Jänne C., Huguet F., Provencher S., Seifert B., Negretti L., Riener M.O., Bonet M., Allal A.S., Ciernik I.F. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J. Clin. Oncol., 2008, Vol. 26, No. 15, рр. 2550–2557.Oehler-Jänne C., Huguet F., Provencher S., Seifert B., Negretti L., Riener M.O., Bonet M., Allal A.S., Ciernik I.F. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J. Clin. Oncol., 2008, Vol. 26, No. 15, рр. 2550–2557.Antoniou T., Tseng A.L. Interactions between antiretrovirals and antineoplastic drug therapy. Clin. Pharmacokinetics, 2005, Vol. 44, No. 2, рр. 111–145.Antoniou T., Tseng A.L. Interactions between antiretrovirals and antineoplastic drug therapy. Clin. Pharmacokinetics, 2005, Vol. 44, No. 2, рр. 111–145.Rudek M.A., Flexner C., Ambinder R.F. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol., 2011, Vol. 12, No. 9, рр. 905–912.Rudek M.A., Flexner C., Ambinder R.F. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol., 2011, Vol. 12, No. 9, рр. 905–912.Powles T., Imami N., Nelson M., Gazzard B., Bower M. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS, 2002, Vol. 16, No. 4, рр. 531–536.Powles T., Imami N., Nelson M., Gazzard B., Bower M. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS, 2002, Vol. 16, No. 4, рр. 531–536.Некрасова А.В., Леонова О.Н., Степанова Е.В., Рассохин В.В. Особенности развития злокачественных опухолей у пациентов с ВИЧ-инфекцией в Санкт-Петербурге // ВИЧ-инфекция и иммуносупрессии. 2016. Т. 8, № 1. С. 31–41. [Nekrasova А.V., Leonova O.N., Stepanova E.V., Rassokhin V.V. Characteristics of tumor development in HIV patients in Saint Petersburg. HIV Infection and Immunosuppressive Disorders, 2014, Vol. 8, No. 1, рр. 31–41 (In Russ.)].Некрасова А.В., Леонова О.Н., Степанова Е.В., Рассохин В.В. Особенности развития злокачественных опухолей у пациентов с ВИЧ-инфекцией в Санкт-Петербурге // ВИЧ-инфекция и иммуносупрессии. 2016. Т. 8, № 1. С. 31–41. [Nekrasova А.V., Leonova O.N., Stepanova E.V., Rassokhin V.V. Characteristics of tumor development in HIV patients in Saint Petersburg. HIV Infection and Immunosuppressive Disorders, 2014, Vol. 8, No. 1, рр. 31–41 (In Russ.)].Suneja G., Boyer M., Yehia B.R., Shiels M.S., Engels E.A., Bekelman J.E., Long J.A. Cancer Treatment in Patients With HIV Infection and Non-AIDS-Defining Cancers: A Survey of US Oncologists. J. Oncol. Pract., 2015, Vol. 11, No. 3, рр. 380–387.Suneja G., Boyer M., Yehia B.R., Shiels M.S., Engels E.A., Bekelman J.E., Long J.A. Cancer Treatment in Patients With HIV Infection and Non-AIDS-Defining Cancers: A Survey of US Oncologists. J. Oncol. Pract., 2015, Vol. 11, No. 3, рр. 380–387.Chiao E.Y., Dezube B.J., Krown S.E., Wachsman W., Brock M.V., Giordano T.P., Mitsuyasu R., Pantanowitz L. Time for oncologists to opt in for routine opt-out HIV testing? JAMA, 2010, Vol. 304, No. 3, рр. 334–339.Chiao E.Y., Dezube B.J., Krown S.E., Wachsman W., Brock M.V., Giordano T.P., Mitsuyasu R., Pantanowitz L. Time for oncologists to opt in for routine opt-out HIV testing? JAMA, 2010, Vol. 304, No. 3, рр. 334–339.Alfa-Wali M., Allen-Mersh T., Antoniou A., Tait D., Newsom-Davis T.B., Gazzard B., Nelson M., Bower M. Chemoradiotherapy for anal cancer in HIV patients causes prolonged CD4 cell count suppression. Ann. Oncol., 2012, Vol. 23, No. 1, рр. 141–147.Alfa-Wali M., Allen-Mersh T., Antoniou A., Tait D., Newsom-Davis T.B., Gazzard B., Nelson M., Bower M. Chemoradiotherapy for anal cancer in HIV patients causes prolonged CD4 cell count suppression. Ann. Oncol., 2012, Vol. 23, No. 1, рр. 141–147.National Program T. Toxicology and Carcinogenesis Studies of Mixtures of 3’-Azido-3’-Deoxythymidine (AZT), Lamivudine (3TC), and Nevirapine (NVP) (CAS Nos. 30516–87–1, 134678–17–4, 129618–40–2) in Genetically Modified C3B6.129F1-Trp53(tm1Brd) N12 Haploinsufficient Mice (in u Natl. Toxicol. Program Genet. Modif. Model Rep., 2013, No. 16, рр. 1.National Program T. Toxicology and Carcinogenesis Studies of Mixtures of 3’-Azido-3’-Deoxythymidine (AZT), Lamivudine (3TC), and Nevirapine (NVP) (CAS Nos. 30516–87–1, 134678–17–4, 129618–40–2) in Genetically Modified C3B6.129F1-Trp53(tm1Brd) N12 Haploinsufficient Mice (in u Natl. Toxicol. Program Genet. Modif. Model Rep., 2013, No. 16, рр. 1.Olivero O.A., Anderson L.M., Diwan B.A. et al. Transplacental effects of 3’-azido-2’,3’-dideoxythymidine (AZT): tumorigenicity in mice and geno- toxicity in mice and monkeys. J. Natl. Cancer Inst., 1997, Vol. 89, No. 21, рр. 1602–1608.Olivero O.A., Anderson L.M., Diwan B.A. et al. Transplacental effects of 3’-azido-2’,3’-dideoxythymidine (AZT): tumorigenicity in mice and geno- toxicity in mice and monkeys. J. Natl. Cancer Inst., 1997, Vol. 89, No. 21, рр. 1602–1608.Chao C., Leyden W.A., Xu L., Horberg M.A., Klein D., Towner W.J., Quesenberry C.P. Jr, Abrams D.I., Silverberg M.J. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS, 2012, Vol. 26, No. 17, рр. 2223–2231.Chao C., Leyden W.A., Xu L., Horberg M.A., Klein D., Towner W.J., Quesenberry C.P. Jr, Abrams D.I., Silverberg M.J. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS, 2012, Vol. 26, No. 17, рр. 2223–2231.Bruyand M., Ryom L., Shepherd L., Fatkenheuer G., Grulich A., Reiss P., de Wit S. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study. J. Acquir. Immune Defic. Syndr., 2015, Vol. 68, No. 5, рр. 568–577.Bruyand M., Ryom L., Shepherd L., Fatkenheuer G., Grulich A., Reiss P., de Wit S. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study. J. Acquir. Immune Defic. Syndr., 2015, Vol. 68, No. 5, рр. 568–577.Duncan K.C., Chan K.J., Chiu C.G., Montaner J.S.G., Coldman A.J., Cescon A., Au-Yeung C.G., Wiseman S.M., Hogg R.S., Press N.M. HAART slows progression to anal cancer in HIV-infected MSM. AIDS, 2014, Vol. 29, No. April 2014, рр. 305–311.Duncan K.C., Chan K.J., Chiu C.G., Montaner J.S.G., Coldman A.J., Cescon A., Au-Yeung C.G., Wiseman S.M., Hogg R.S., Press N.M. HAART slows progression to anal cancer in HIV-infected MSM. AIDS, 2014, Vol. 29, No. April 2014, рр. 305–311.Powles T., Robinson D., Stebbing J., Shamash J., Nelson M., Gazzard B., Mandelia S., Møller H., Bower M. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J. Clin. Oncol., 2009, Vol. 27, No. 6, рр. 884–890.Powles T., Robinson D., Stebbing J., Shamash J., Nelson M., Gazzard B., Mandelia S., Møller H., Bower M. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J. Clin. Oncol., 2009, Vol. 27, No. 6, рр. 884–890.Varadarajan J., McWilliams M.J., Hughes S.H. Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations. Proc. Natl. Acad. Sci., 2013, Vol. 2013, рр. 1–6.Varadarajan J., McWilliams M.J., Hughes S.H. Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations. Proc. Natl. Acad. Sci., 2013, Vol. 2013, рр. 1–6.Aberle D.R., Adams A.M., Berg C.D., Black W.C., Clapp J.D., Fagerstrom R.M., Gareen I.F., Gatsonis C., Marcus P.M., Sicks J.D. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med., 2011, Vol. 365, No. 5, рр. 395–409.Aberle D.R., Adams A.M., Berg C.D., Black W.C., Clapp J.D., Fagerstrom R.M., Gareen I.F., Gatsonis C., Marcus P.M., Sicks J.D. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med., 2011, Vol. 365, No. 5, рр. 395–409.Hulbert A., Hooker C.M., Keruly J.C. Prospective CT screening for lung cancer in a high-risk population: HIV-positive smokers. J. Thorac. Oncol., 2014, Vol. 9, No. 6, рр. 752–759.Hulbert A., Hooker C.M., Keruly J.C. Prospective CT screening for lung cancer in a high-risk population: HIV-positive smokers. J. Thorac. Oncol., 2014, Vol. 9, No. 6, рр. 752–759.Sigel K., Wisnivesky J., Shahrir S., Brown S.T., Justice A., Kim J., Rodriguez-Barradas M.C., Akgün K.M., Rimland D., Hoo G.W., Soo C.K. Findings in asymptomatic HIV-infected patients undergoing chest computed tomography testing: implications for lung cancer screening. AIDS, 2014, Vol. 28, No. 7, рр. 1007–1014.Sigel K., Wisnivesky J., Shahrir S., Brown S.T., Justice A., Kim J., Rodriguez-Barradas M.C., Akgün K.M., Rimland D., Hoo G.W., Soo C.K. Findings in asymptomatic HIV-infected patients undergoing chest computed tomography testing: implications for lung cancer screening. AIDS, 2014, Vol. 28, No. 7, рр. 1007–1014.Helleberg M., Afzal S., Kronborg G., Larsen C.S., Pedersen G., Pedersen C., Gerstoft J., Nordestgaard B.G., Obel N. Mortality attributable to smoking among HIV-1-infected individuals: A nationwide, population-based cohort study. Clin. Infect. Dis., 2013, Vol. 56, No. 5, рр. 727–734.Helleberg M., Afzal S., Kronborg G., Larsen C.S., Pedersen G., Pedersen C., Gerstoft J., Nordestgaard B.G., Obel N. Mortality attributable to smoking among HIV-1-infected individuals: A nationwide, population-based cohort study. Clin. Infect. Dis., 2013, Vol. 56, No. 5, рр. 727–734.Shirley D.K., Kesari R.K., Glesby M.J. Factors Associated with Smoking in HIV-Infected Patients and Potential Barriers to Cessation. AIDS Patient Care STDS, 2013, Vol. 27, No. 11, рр. 604–612.Shirley D.K., Kesari R.K., Glesby M.J. Factors Associated with Smoking in HIV-Infected Patients and Potential Barriers to Cessation. AIDS Patient Care STDS, 2013, Vol. 27, No. 11, рр. 604–612.Crothers K., Goulet J.L., Rodriguez-Barradas M.C. et al. Decreased awareness of current smoking among health care providers of HIV-positive compared to HIV-negative veterans. J. Gen. Intern. Med., 2007, Vol. 22, No. 6, рр. 749–754.Crothers K., Goulet J.L., Rodriguez-Barradas M.C. et al. Decreased awareness of current smoking among health care providers of HIV-positive compared to HIV-negative veterans. J. Gen. Intern. Med., 2007, Vol. 22, No. 6, рр. 749–754.Stead L.F., Bergson G., Lancaster T. Physician advice for smoking cessation Cochrane Database of Systematic. Reviews, 2008, No. 2.Stead L.F., Bergson G., Lancaster T. Physician advice for smoking cessation Cochrane Database of Systematic. Reviews, 2008, No. 2.Lloyd-Richardson E.E., Stanton C.A., Papandonatos G.D., Shadel W.G., Stein M., Tashima K., Flanigan T., Morrow K., Neighbors C., Niaura R. Motivation and patch treatment for HIV+ smokers: A randomized controlled trial. Addiction, 2009, Vol. 104, No. 11, рр. 1891–1900.Lloyd-Richardson E.E., Stanton C.A., Papandonatos G.D., Shadel W.G., Stein M., Tashima K., Flanigan T., Morrow K., Neighbors C., Niaura R. Motivation and patch treatment for HIV+ smokers: A randomized controlled trial. Addiction, 2009, Vol. 104, No. 11, рр. 1891–1900.Cui Q., Robinson L., Elston D., Smaill F., Cohen J., Quan C. Safety and tolerability of varenicline tartrate (Champix/Chantix) for smoking ces- sation in HIV-infected subjects: A pilot open-label study. AIDS Patient Care STDS, 2012, Vol. 26, No. 1, рр. 12–19.Cui Q., Robinson L., Elston D., Smaill F., Cohen J., Quan C. Safety and tolerability of varenicline tartrate (Champix/Chantix) for smoking ces- sation in HIV-infected subjects: A pilot open-label study. AIDS Patient Care STDS, 2012, Vol. 26, No. 1, рр. 12–19.Potsch D.V., Oliveira M.L.A., Ginuíno C., Miguel J.C., Oliveira S.A.N., Silva E.F., Moreira R.B., Cruz G.V.M., Oliveira A.L.V.S.M., Camacho L.A.B., Barroso P.F. High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects. Vaccine, 2010, Vol. 28, No. 6, рр. 1447–1450.Potsch D.V., Oliveira M.L.A., Ginuíno C., Miguel J.C., Oliveira S.A.N., Silva E.F., Moreira R.B., Cruz G.V.M., Oliveira A.L.V.S.M., Camacho L.A.B., Barroso P.F. High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects. Vaccine, 2010, Vol. 28, No. 6, рр. 1447–1450.El-Serag H.B., Davila J.A. Surveillance for hepatocellular carcinoma: in whom and how? Therap. Adv. Gastroenterol., 2011, Vol. 4, No. 1, рр. 5–10.El-Serag H.B., Davila J.A. Surveillance for hepatocellular carcinoma: in whom and how? Therap. Adv. Gastroenterol., 2011, Vol. 4, No. 1, рр. 5–10.Goncalves P.H., Montezuma-Rusca J.M., Yarchoan R., Uldrick T.S. Cancer prevention in HIV-infected populations Seminars in Oncology. Elsevier, 2016, Vol. 43, No. 1, рр. 173–188.Goncalves P.H., Montezuma-Rusca J.M., Yarchoan R., Uldrick T.S. Cancer prevention in HIV-infected populations Seminars in Oncology. Elsevier, 2016, Vol. 43, No. 1, рр. 173–188.Moyer V.A. Screening for Cervical Cancer: U.S. preventive services task force recommendation statement. Annals Int. Med., 2012, Vol. 156, No. 12, рр. 880–891.Moyer V.A. Screening for Cervical Cancer: U.S. preventive services task force recommendation statement. Annals Int. Med., 2012, Vol. 156, No. 12, рр. 880–891.Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults. AIDSinfo, 2015, рр. 1–411.Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults. AIDSinfo, 2015, рр. 1–411.Дианова Т.В. Возможные пути профилактики рака шейки матки у ВИЧ-инфицированных женщин // Сибирский медицинский журнал. 2010. T. 97, № 6. С. 113–115. [Dianova T.V. Possible ways of cervical cancer prevention in HIV-infected women. Siberian Medical Journal, 2010, Vol. 97, No. 6, pp. 113–115 (In Russ.)].Дианова Т.В. Возможные пути профилактики рака шейки матки у ВИЧ-инфицированных женщин // Сибирский медицинский журнал. 2010. T. 97, № 6. С. 113–115. [Dianova T.V. Possible ways of cervical cancer prevention in HIV-infected women. Siberian Medical Journal, 2010, Vol. 97, No. 6, pp. 113–115 (In Russ.)].Мартиросян М.М. Заболевания шейки матки, ассоциированные с вирусом папилломы человека, у ВИЧ-инфицированных женщин в Санкт-Петербурге: дисс. … канд. мед. наук. 2015. 140 с. [Martirosyan M.M. Diseases of the cervix associated with human papilloma virus, among HIV-infected women in St. Petersburg: Candidate’s thesis. Saint-Petersburg, 2015, 140 p. (In Russ.)].Мартиросян М.М. Заболевания шейки матки, ассоциированные с вирусом папилломы человека, у ВИЧ-инфицированных женщин в Санкт-Петербурге: дисс. … канд. мед. наук. 2015. 140 с. [Martirosyan M.M. Diseases of the cervix associated with human papilloma virus, among HIV-infected women in St. Petersburg: Candidate’s thesis. Saint-Petersburg, 2015, 140 p. (In Russ.)].Goldie S.J., Kuntz K.M., Weinstein M.C., Freedberg K.A., Welton M.L., Palefsky J.M. The clinical effectiveness and cost-effectiveness of scree- ning for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA, 1999, Vol. 281, No. 19, рр. 1822–1829.Goldie S.J., Kuntz K.M., Weinstein M.C., Freedberg K.A., Welton M.L., Palefsky J.M. The clinical effectiveness and cost-effectiveness of scree- ning for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA, 1999, Vol. 281, No. 19, рр. 1822–1829.Harro C.D., Pang Y.S., Roden R.B.S., Hildesheim A., Wang Z., Reynolds M.J. et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst., 2001, Vol. 93, No. 4, рр. 284–292.Harro C.D., Pang Y.S., Roden R.B.S., Hildesheim A., Wang Z., Reynolds M.J. et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst., 2001, Vol. 93, No. 4, рр. 284–292.Kemp T.J., Safaeian M., Hildesheim A., Pan Y., Penrose K.J., Porras C., Schiller J.T., Lowy D.R., Herrero R., Pinto L.A. Kinetic and HPV infec- tion effects on cross-type neutralizing antibody and avidity responses induced by Cervarix®. Vaccine, 2012, Vol. 31, No. 1, рр. 165–170.Kemp T.J., Safaeian M., Hildesheim A., Pan Y., Penrose K.J., Porras C., Schiller J.T., Lowy D.R., Herrero R., Pinto L.A. Kinetic and HPV infec- tion effects on cross-type neutralizing antibody and avidity responses induced by Cervarix®. Vaccine, 2012, Vol. 31, No. 1, рр. 165–170.Palefsky J.M., Giuliano A.R., Goldstone S., Moreira E.D. Jr, Aranda C., Jessen H., Hillman R., Ferris D., Coutlee F., Stoler M.H. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N. Engl. J. Med., 2011, Vol. 365, No. 17, рр. 1576–1585.Palefsky J.M., Giuliano A.R., Goldstone S., Moreira E.D. Jr, Aranda C., Jessen H., Hillman R., Ferris D., Coutlee F., Stoler M.H. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N. Engl. J. Med., 2011, Vol. 365, No. 17, рр. 1576–1585.Levin M.J., Moscicki A.B., Song L.Y., Fenton T., Meyer W.A. 3rd, Read J.S., Handelsman E.L., Nowak B., Sattler C.A., Saah A., Radley D.R., Esser M.T., Weinberg A. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J. Acquir. Immune Defic. Syndr., 2010, Vol. 55, No. 2, рр. 197–204.Levin M.J., Moscicki A.B., Song L.Y., Fenton T., Meyer W.A. 3rd, Read J.S., Handelsman E.L., Nowak B., Sattler C.A., Saah A., Radley D.R., Esser M.T., Weinberg A. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J. Acquir. Immune Defic. Syndr., 2010, Vol. 55, No. 2, рр. 197–204.Toft L., Storgaard M., Müller M., Sehr P., Bonde J., Tolstrup M., Østergaard L., Søgaard O.S. Comparison of the Immunogenicity and Reactogenicity of Cervarix(R) and Gardasil(R) Human Papillomavirus Vaccines in HIV-infected Adults: A Randomized, Double-Blind, Clinical Trial. J. Infect. Dis., 2014, Vol. 209, No. 8, pp. 1165–1173.Toft L., Storgaard M., Müller M., Sehr P., Bonde J., Tolstrup M., Østergaard L., Søgaard O.S. Comparison of the Immunogenicity and Reactogenicity of Cervarix(R) and Gardasil(R) Human Papillomavirus Vaccines in HIV-infected Adults: A Randomized, Double-Blind, Clinical Trial. J. Infect. Dis., 2014, Vol. 209, No. 8, pp. 1165–1173.

The authors declare that there are no conflicts of interest present.